Zoryve cream 0.15% improves atopic dermatitis across diverse skin types

Key takeaways:

• More than a quarter of patients achieved a clear or almost clear IGA score as well as a 2-grade improvement from baseline.
• Adverse events were low across skin types.

Zoryve cream 0.15% continues to show that it can provide clinical improvement to patients with atopic dermatitis, according to a press release.

Presented at the European Academy of Dermatology & Venereology Congress 2024, new phase 3 results from the INTEGUMENT-1 and -2 trials show that Zoryve (roflumilast, Arcutis) cream 0.15% can alleviate atopic dermatitis in all skin types.

“We know that the clinical presentation of atopic dermatitis (AD) can vary by race, ethnicity and Fitzpatrick skin type,” Vimal H. Prajapati, FRCPC, DABD, clinical associate professor at the University of Calgary and co-founder/co-director of the Skin Health & Wellness Centre, Dermphi Centre, Dermphi Shop and Dermatology Research Institute, told Healio. “This subgroup analysis showed that Zoryve cream 0.15% provided consistent relief of the signs and symptoms of AD and was safe and well-tolerated across all subgroups.”

Vimal H. Prajapati

In the study, more than a quarter of all patients treated with Zoryve achieved IGA-AD scores of clear or almost clear and a 2-grade improvement from baseline by week 4 compared with vehicle. Asian patients treated with Zoryve saw the best outcomes (33.7% vs. 21.8%), followed by “other” (33.2% vs. 13.7%), white (32.3% vs. 13.3%) and Black or African American (25.8% vs. 11.5%) compared with vehicle-treated patients. Hispanic or Latino patients also saw positive outcomes (32.9% vs. 16.5%).

Compared with vehicle, Zoryve also relieved itching across all races, including white (33.5% vs. 16.5%) Black or African American (30.6% vs. 21%), Asian (25.4% vs. 7.9%) and “other” (34.3% vs. 22.7%), as well as across ethnicities, including Hispanic or Latino (37.4% vs. 30.5%) and not Hispanic or Latino (30.9% vs. 13.8%).

According to the press release, treatment-emergent adverse event rates were also low in all groups.

“It is important to see clinical trial data that reflects the diversity of our patients, and that investigators and trial sponsors continue to work together to enroll from a broad population,” Prajapati said. “These data can give confidence to clinicians that Zoryve cream 0.15% can be safe and effective for their patients with AD including those with diverse skin types.”

Editor's note: On Sept. 26, the article was updated with a quote from Vimal H. Prajapati, FRCPC, DABD.

Reference:

• Prajapati VH, et al. Once-daily roflumilast cream 0.15% for the treatment of atopic dermatitis in patients with diverse skin types: Pooled subgroup analysis from the phase 3 INTEGUMENT-1 and-2 trials. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 25-28, 2024; Amsterdam.